Circulating omentin-1 levels and inflammation in polycystic ovary syndrome by Franik, Grzegorz et al.
308
ORIGINAL PAPER /  G Y N E CO LO G Y
Ginekologia Polska
2020, vol. 91, no. 6, 308–312
Copyright © 2020 Via Medica
ISSN 0017–0011
DOI 10.5603/GP.2020.0057
Corresponding author:
Magdalena Olszanecka-Glinianowicz
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, 18 Medyków St, 40–752 Katowice, Poland
e-mail: magolsza@gmail.com
Circulating omentin-1 levels and inflammation  
in polycystic ovary syndrome
Grzegorz Franik1 , Marcin Sadlocha2 , Pawel Madej1 , Aleksander Owczarek3 ,  
Violetta Skrzypulec-Plinta4 , Ryszard Plinta4 , Jerzy Chudek5,6 ,  
Magdalena Olszanecka-Glinianowicz7
1Department of Endocrinological Gynecology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland 
2Women’s Health Chair, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland 
3Department of Statistics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland 
4Chair of Physiotherapy, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland 
5Pathophysiology Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice,  
Medical University of Silesia, Katowice, Poland  
6Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice,  
Medical University of Silesia, Katowice, Poland 
7Health Promotion and Obesity Management Unit, Department of Pathophysiology,  
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
ABSTRACT
Objectives: The aim of the study was to analyze interrelation between plasma omentin-1 levels and nutritional status and 
inflammation in PCOS.
Material and methods: A cross-sectional study involving 86 PCOS (47 obese) and 72 Non-PCOS women (41 obese) deter-
mined anthropometric parameters and body composition. Serum glucose, insulin and omentin-1, TNF-α, sTNFRs, IL-6 and 
sR-IL6 were measured in the fasting state. 
Results: Plasma omentin-1 levels were significantly lower in the PCOS than in the Non-PCOS group and both correspond-
ing normal weight and obese subgroups. In three analyzed least-angle regression (LARS) models the lower plasma omen-
tin-1 levels was associated with PCOS occurrence, higher circulating TNF-α and lower IL-6 levels.
Conclusions: Suppressed omentin-1 levels in PCOS are characteristic for this disturbance and proinflammatory cytokines 
are factors modifying secretion of this adipokine.  
Key words: omentin-1; inflammation; nutritional status; PCOS
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INTRODUCTION
Omentin-1 is an adipokine, released mainly by stro-
mal-vascular cells of adipose tissue [1–3]. The highest omentin 
mRNA expression was shown in visceral and pericardial adi-
pose tissues, while in subcutaneous is twenty times lower [3].
It has been shown in an experimental model that 
omentin-1 stimulates Akt phosphorylation and increases 
insulin-stimulated glucose uptake [2]. In addition, omen-
tin-1 exerts anti-inflammatory properties, and is also associ-
ated with decreased cardiovascular risk [4]. Notably, circulat-
ing omentin-1 levels are higher in women than in men [5].
Decreased expression, secretion and circulating levels of 
omentin-1 were shown in obese subjects [5]. Moreover, neg-
ative correlations between omentin-1 concentrations and 
BMI, waist circumference, circulating leptin and insulin levels 
and positive with adiponectin levels were observed [5]. In 
addition, an inhibiting effect of high CRP levels on omen-
tin-1 concentrations was found [6]. It has also been shown 
that weight loss is followed by omentin-1 level increase, 
proportional to the improvement in insulin sensitivity ac-
companied by a decrease of insulin levels [7]. Furthermore, 
12-weeks of aerobic training causing decreased fat depots 
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without changes in body mass was followed by an increase 
in circulating omentin-1 levels [8]. 
The results of studies assessing omentin-1 levels in PCOS 
are inconsistent. Its lower circulating levels were shown 
independent from nutritional status and inversely associ-
ated with androgens and CRP levels [9]. While, no difference 
between normal weight PCOS and Non-PCOS women was 
shown despite higher insulin levels and marked insulin 
resistance in PCOS group [10]. Contrary, Than et al. [6] ob-
served that metformin therapy increased omentin-1 levels 
in PCOS women. 
Recently, we have suggested an impairment of hor-
monal stroma adipose tissue function regardless of the 
nutritional status, secondary to insulin resistance and hy-
perandrogenism in PCOS [11]. We have also found that 
low grade inflammation is related to nutritional status, in-
dependently from PCOS occurrence [12]. So far, only one 
study documented negative correlation between levels 
of omentin-1 and IL-6 and TNF-α in PCOS women in the 
Asian group [13]. 
The aim of the study was to analyze interrelation be-
tween plasma omentin-1 levels and nutritional status and 
inflammation in PCOS women.
MATERIAL AND METHODS 
The cross-sectional study involved 86 PCOS women 
(39 normal weight and 47 obese) with stable body mass 
during last 3-month period diagnosed in Department of 
Endocrinological Gynecology from 2013 to 2014. The di-
agnosis of PCOS was based on Rotterdam ESHRE/ASRM 
criteria from 2003 [14]. Seventy-two women without PCOS 
(31 normal weight and 41 obese) constitute the control 
group. Patients with Cushing’s syndrome, thyroid dysfunc-
tions, androgen secreting tumor, and enzyme deficiency 
(21-hydroxylase in particular), decreased ovary reserves, 
type 1 and 2 diabetes were not enrolled. Any pharmacologi-
cal therapy, smoking and alcohol abuse were among the 
exclusion criteria. The study was conducted after obtain-
ing of the informed consent from each participant. Study 
protocol was approved by the Ethical Committee of Medical 
University of Silesia.
Normal weight was defined as body mass index (BMI) 
from 18.5 to 24.9 kg/m2 and obesity as > 30.0 kg/m2. The 
characteristics of the study groups are presented in Table 1. 
All the study women were tested within 3 and 5 days 
of menstrual cycle. Anthropometric measurements (body 
mass, height and waist circumference) were performed, 
and BMI was calculated according to the standard formula. 
Body composition was assessed by bioimpedance method 
using Bodystat 1500 (Douglas, Isle of Man). 15 mL samples 
of venous blood were withdrawn in the morning between 
8.00–9.00 a.m., after an overnight fast (16 h). The blood 
samples were collected according to recommendation of 
manufacturer of the kits. Serum and plasma samples were 
stored frozen in –70°C.
Laboratory procedures 
Plasma glucose was estimated by colorimetric meth-
ods using the commercially available test kits (Roche, Swit-
zerland). Serum insulin concentration was determined by 
enzyme-linked immunosorbent assay (ELISA) (DRG Instru-
ments GmbH, Marburg, Germany) with a lower limit of sen-
sitivity of 1.76 mIU/mL and intra- and inter-assay coefficients 
of variations of 2.2% and 4.4%, respectively. HOMA-IR index 
was calculated with the standard formula: HOMA-IR = fasting 
concentration of insulin (mIU/mL) × fasting concentration of 
glucose (mmol/L)/ 22.5.
ELISA method was also used for measurements of plas-
ma omentin-1 levels (BioVendor, Brno, Czech Republic) with 
the lower limit of sensitivity of 0.5 ng/mL and intra- and 
inter-assay coefficients of variations were 3.65% and 4.6%, 
respectively as well as TNF-α, sTNFR1, sTNFR2, IL-6 and 
sR-IL-6 (R&D Systems, Michigan, USA) with the lower limit 
of sensitivity 0.18 pg/mL, 0.77 pg/mL, 0.6 pg/mL, 0.5 pg/mL 
and 0.88 pg/mL, respectively and intra- and inter-assay co-
efficients of variations were 14.4% and 18.7% respectively 
for TNF-α, 3.6% and 2.6% respectively for sTNFR1, 3.7% and 
3.5% respectively for sTNFR2, 16.8% and 17.2% respectively 
for IL-6 and 9.7% and 9.6% respectively for sR-IL-6. 
Statistical analysis
Statistical analyses were performed using STATISTICA 
9.0 PL (StatSoft Poland) software and R software environ-
ment. There was no missing data in the database. The results 
are presented as mean values ± standard deviation. Distribu-
tion of variables was evaluated by the D’Agostino-Pearson 
test. Homogeneity of variances was assessed by the Levene 
test. Quantitative variables were compared with two-way 
multivariate analysis of variances with Duncan test post-hoc. 
The assessment of association between variables was done 
with the multivariate linear regression and the backward 
stepwise procedure. Outliers were identified based on 
Cook’s distance values. The Cook-Weisberg test was used 
to test the residuals for heteroskedasticity. Models calcula-
tion was performed including evaluation of multicollinear-
ity, which was assessed with the variance inflation factor 
(VIF). The VIF should not exceed more than five. Goodness 
of fit of obtained model was assessed with the F test and 
determination coefficient R2. All results were considered as 
statistically significant with a p value of < 0.05.
RESULTS
The age of both obese subgroups (PCOS and Non-PCOS) 
as well as of normal weight subgroups (PCOS and Non-PCOS) 
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was similar (Tab. 1). Body mass and BMI did not differ be-
tween the corresponding subgroups of PCOS and Non-PCOS.
The serum concentrations of glucose, insulin and HO-
MA-IR values were significantly higher in the PCOS group 
than in the Non-PCOS group. As expected, in the obese PCOS 
subgroup, serum concentration of insulin and HOMA-IR 
value were significantly higher than in normal weight PCOS 
subgroup (Tab. 1).
Plasma omentin-1 levels were significantly lower in the 
PCOS group than in the Non-PCOS group. The lower plasma 
omenntin-1 levels were shown in normal weight and obese 
PCOS than in both corresponding Non-PCOS subgroups (Tab. 1). 
There were no differences in plasma TNF-α, TNFR1, IL-6 and 
sR-IL-6 levels between the PCOS and Non-PCOS groups, while 
TNFR2 levels were significantly higher in the PCOS group. 
However, plasma TNF-α and IL-6 levels were significantly 
higher in both obese PCOS and Non-POS than in correspond-
ing normal weight subgroups. The highest sTNFR1 levels were 
observed in the obese PCOS subgroup. While, sTNFR2 and 
sR-IL-6 levels were significantly higher in obese than normal 
weight PCOS subgroups and significantly lower in obese 
than normal weight Non-PCOS subgroups (Tab. 1).
Multiple regression analyses 
In Table 2, presented are three analyzed Least-angle 
regression (LARS) models. Numbers denote sequence of 
switching on of the variable model. The best results, the low-
est fault model fit to the data, in each case, was obtained for 
a set of three variables. The lower plasma omentin-1 levels 
were associated with PCOS occurrence, higher circulating 
TNF-α and lower IL-6 levels (Tab. 2). 
DISCUSSION
Numerous studies published in recent years, including 
ours, suggested that hormonal dysfunction of adipose tis-
sue is an important link in PCOS pathogenesis [11, 15–18]. 
Obesity, especially visceral, is well known risk factor of PCOS 
development in genetically predisposed women [19, 20]. 
Inflammation in visceral adipose tissue is a key factor affect-
ing the release of adipokines [21]. The changes in the profile 
of circulating adipokines were shown to be associated with 
the development of insulin resistance and both pituitary 
and ovary hormonal dysfunction [22].  
The previously published studies have shown lower plas-
ma omentin-1 levels in PCOS women, independently from 
nutritional status [6, 9, 11]. Contrary to some studies [5, 10] 
we did not observe the association between plasma omen-
tin-1 levels and anthropometric parameters. This discrepancy 
is difficult to explain. However, the results of our recently pub-
lished study suggest that hormonal dysfunction of stromal 
cells of adipose tissue is the result, but not a cause of insulin 
resistance development [11]. This hypothesis is supported 
by the fact that HOMA-IR values in the obese non-PCOS sub-
group were below the cut-off point for the insulin resistance. 
Moreover, Cai et al. [23] revealed that the impaired function 
of stromal cells of adipose tissue is strongly associated with 
insulin resistance. This may explain lower omentin-1 levels 
in the obese, but not in the normal weight PCOS subgroup. 
Based on our own and other studies [9, 11] we suggest that 
androge ns may be an important factor in explaining dis-
turbances of hormonal function of stromal cells of adipose 
tissue. Disturbances of omentin-1 synthesis in adipose tissue 
are not the primary effect of visceral fat accumulation, but 
rather secondary to the development of insulin resistance 
and hormonal disturbances [11]. However, inflammation in 
visceral adipose tissue may be an important cause for de-
creased omentin-1 synthesis. As it was mentioned above, 
a single study performed in an Asian PCOS group showed 
a negative correlation between omentin-1 and IL-6 and TNF-α 
levels [13]. In accordance with this data, multiple regression 
analysis in the current study showed a negative impact of 
TNF-α on omentin-1 levels. However, this association is con-
troversial, as TNF-α levels were significantly lower in the nor-
mal weight PCOS group than both obese PCOS and Non-PCOS 
subgroups. In addition, TNF-α levels were similar in normal 
weight PCOS and Non-PCOS subgroups. These results are in 
accordance with our study published over 10 years ago that 
PCOS is not associated with chronic inflammation per se [24]. 
Contrary to previously published data, our study regression 
model suggests that IL-6 may stimulate omentin-1 synthe-
sis. This discrepancy is difficult to explain, but potentially 
related to the dual, proinflammatory and anti-inflammatory 
function of IL-6. It should be noted that the proinflammatory 
properties of cytokines do not correspond to lower circulating 
omentin-1 levels in normal weigh and obese PCOS showing 
expected differences in TNF-α and IL-6 levels [12, 25]. Our 
study suggests that the mechanism of stromal cells dysfunc-
Table 2. The models regression type LARS and the resulting model 
of the impact of variable on plasma omentin-1 levels
Variable 
y = log10(Omentin-1) [ng/mL]
Model 
I
Model 
II
Model 
III
Final 
model
PCOS ± 1 1 1 –0.2432
BMI [kg/m2] 8 – – –
Fat percentage [%] – 8 – –
Waist circumference [cm] – – 8 –
log10(HOMA-IR) 7 7 7 –
log10(TNF-α) [pg/mL] 3 3 3 –0.0652
log10(sTNF-R1) [pg/mL] 5 5 5 –
sTNF-R2 [pg/mL] 6 6 6 –
log10(IL-6) [pg/mL] 2 2 2 0.0745
log10(sR-IL6) [pg/mL] 4 4 4 –
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tion in adipose tissue in PCOS is more complex, including 
impact of insulin resistance, androgens and proinflamma-
tory cytokines. However, these factors may explain lower 
omentin-1 levels in obese PCOS, it does not fully elucidate the 
cause of its decreased release in normal weight PCOS. Thus, 
the relationship between this cytokine and omentin-1 levels 
requires experimental studies on cell cultures assessing the 
effect of this cytokine on omentin-1 expression. Although, 
it cannot be excluded that the decreased concentration of 
circulating omentin-1 in PCOS women with normal body 
mass is the result of its' disturbed secretion in ovaries, but 
not in adipose tissue [26]. Verification of this hypothesis also 
requires further experimental studies.
The limitation of our study is the size of the study sub-
groups and the lack of separation of PCOS with normal 
weight for subgroups with and without metabolic obesity. 
Moreover, the distribution of body fat and its visceral de-
posits were not directly assessed using DEXA or CT scanner. 
Additionally, in our study, the impact of selected adipokines 
on omentin-1 levels has not been analyzed. 
CONCLUSIONS
Suppressed omentin-1 levels in PCOS are characteristic 
for this disturbance whereas proinflammatory cytokines are 
factors modifying secretion of this adipokine.  
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